Lantheus Holdings, Inc. (LNTH)
USD 102.13
(0.13%)
USD 102.13
(0.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -96.71 Million USD | -167.91% |
| 2022 | 142.41 Million USD | 86.76% |
| 2021 | 76.25 Million USD | -45.06% |
| 2020 | 138.78 Million USD | 37.21% |
| 2019 | 101.15 Million USD | -33.91% |
| 2018 | 153.05 Million USD | -20.22% |
| 2017 | 191.85 Million USD | -15.46% |
| 2016 | 226.93 Million USD | -30.16% |
| 2015 | 324.91 Million USD | -16.16% |
| 2014 | 387.54 Million USD | -0.24% |
| 2013 | 388.45 Million USD | 6.28% |
| 2012 | 365.5 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -155.07 Million USD | -60.35% |
| 2024 Q2 | -136.74 Million USD | 11.82% |
| 2023 FY | -96.71 Million USD | -167.91% |
| 2023 Q3 | 1.56 Million USD | -99.11% |
| 2023 Q4 | -96.71 Million USD | -6279.55% |
| 2023 Q1 | 88.09 Million USD | -38.14% |
| 2023 Q2 | 176.79 Million USD | 100.69% |
| 2022 Q4 | 142.41 Million USD | 291.22% |
| 2022 Q2 | 14.08 Million USD | -78.95% |
| 2022 Q1 | 66.89 Million USD | -12.28% |
| 2022 FY | 142.41 Million USD | 86.76% |
| 2022 Q3 | -74.47 Million USD | -628.87% |
| 2021 FY | 76.25 Million USD | -45.06% |
| 2021 Q1 | 112.86 Million USD | -18.68% |
| 2021 Q2 | 88.12 Million USD | -21.92% |
| 2021 Q3 | 85.62 Million USD | -2.84% |
| 2021 Q4 | 76.25 Million USD | -10.94% |
| 2020 FY | 138.78 Million USD | 37.21% |
| 2020 Q1 | 95.91 Million USD | -5.17% |
| 2020 Q3 | 134.81 Million USD | -1.48% |
| 2020 Q4 | 138.78 Million USD | 2.95% |
| 2020 Q2 | 136.84 Million USD | 42.67% |
| 2019 Q2 | 141.95 Million USD | -7.87% |
| 2019 Q4 | 101.15 Million USD | -14.62% |
| 2019 FY | 101.15 Million USD | -33.91% |
| 2019 Q1 | 154.08 Million USD | 0.67% |
| 2019 Q3 | 118.47 Million USD | -16.54% |
| 2018 Q4 | 153.05 Million USD | -5.69% |
| 2018 Q1 | 193.98 Million USD | 1.11% |
| 2018 FY | 153.05 Million USD | -20.22% |
| 2018 Q2 | 180.83 Million USD | -6.78% |
| 2018 Q3 | 162.29 Million USD | -10.25% |
| 2017 Q4 | 191.85 Million USD | -4.17% |
| 2017 FY | 191.85 Million USD | -15.46% |
| 2017 Q3 | 200.19 Million USD | -5.36% |
| 2017 Q2 | 211.52 Million USD | -7.31% |
| 2017 Q1 | 228.2 Million USD | 0.56% |
| 2016 Q4 | 226.93 Million USD | -7.39% |
| 2016 FY | 226.93 Million USD | -30.16% |
| 2016 Q1 | 314.11 Million USD | -3.32% |
| 2016 Q2 | 297.63 Million USD | -5.25% |
| 2016 Q3 | 245.03 Million USD | -17.67% |
| 2015 Q3 | 332.09 Million USD | -0.08% |
| 2015 Q4 | 324.91 Million USD | -2.16% |
| 2015 Q2 | 332.37 Million USD | -11.74% |
| 2015 Q1 | 376.6 Million USD | -2.82% |
| 2015 FY | 324.91 Million USD | -16.16% |
| 2014 Q4 | 387.54 Million USD | 1.96% |
| 2014 FY | 387.54 Million USD | -0.24% |
| 2014 Q1 | 390.08 Million USD | 0.42% |
| 2014 Q2 | 396.63 Million USD | 1.68% |
| 2014 Q3 | 380.09 Million USD | -4.17% |
| 2013 FY | 388.45 Million USD | 6.28% |
| 2013 Q1 | 370.58 Million USD | 1212.15% |
| 2013 Q3 | 386.24 Million USD | -0.6% |
| 2013 Q2 | 388.57 Million USD | 4.86% |
| 2013 Q4 | 388.45 Million USD | 0.57% |
| 2012 Q4 | -33.32 Million USD | 0.0% |
| 2012 FY | 365.5 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 122.215% |
| Embecta Corp. | 1.31 Billion USD | 107.371% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 202.657% |
| Dynavax Technologies Corporation | 106.63 Million USD | 190.693% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 121.084% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 122.348% |
| PainReform Ltd. | -7.95 Million USD | -1116.478% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 229.033% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -518.562% |
| SCYNEXIS, Inc. | -19.35 Million USD | -399.793% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -925.586% |
| Cosmos Health Inc. | 8.59 Million USD | 1225.745% |
| Journey Medical Corporation | -9.7 Million USD | -896.086% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -518.562% |
| Safety Shot Inc | -2.28 Million USD | -4133.543% |
| Alpha Teknova, Inc. | 1.97 Million USD | 4999.189% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 26.079% |
| Bright Green Corporation | 1.84 Million USD | 5351.058% |
| Procaps Group, S.A. | 242.93 Million USD | 139.809% |
| Theratechnologies Inc. | 24.87 Million USD | 488.846% |
| Harrow Health, Inc. | 116.41 Million USD | 183.072% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -3737.698% |
| Biofrontera Inc. | 4.05 Million USD | 2484.369% |
| DURECT Corporation | -7.65 Million USD | -1163.522% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -188.454% |
| Cronos Group Inc. | -663.32 Million USD | 85.42% |
| OptiNose, Inc. | 58.06 Million USD | 266.555% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 115.514% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -563.67% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -1764.817% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 744.175% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -1420.682% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 90602.438% |
| Radius Health, Inc. | 359.28 Million USD | 126.918% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 49139.344% |
| ProPhase Labs, Inc. | 19.23 Million USD | 602.886% |
| Phibro Animal Health Corporation | 454.84 Million USD | 121.262% |
| Procaps Group S.A. | 242.93 Million USD | 139.809% |
| Alvotech | 1.06 Billion USD | 109.087% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 2729.418% |
| Viatris Inc. | 17.13 Billion USD | 100.565% |
| Rockwell Medical, Inc. | 4.45 Million USD | 2270.332% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -1882.981% |
| SIGA Technologies, Inc. | -148.68 Million USD | 34.955% |
| Tilray Brands, Inc. | 158.97 Million USD | 160.833% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 179.337% |
| Shineco, Inc. | 29.29 Million USD | 430.178% |
| PetIQ, Inc. | 351.93 Million USD | 127.48% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -3233.186% |
| Incannex Healthcare Limited | -5.48 Million USD | -1663.172% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 154.546% |
| Alimera Sciences, Inc. | 55.3 Million USD | 274.854% |
| Silver Spike Investment Corp. | -32.61 Million USD | -196.551% |
| Assertio Holdings, Inc. | -32.52 Million USD | -197.304% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -6396.176% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -1811.12% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -1908.932% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -1077.455% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 2393.336% |
| Hempacco Co., Inc. | 13.61 Million USD | 810.336% |
| Talphera, Inc. | -5.72 Million USD | -1590.439% |
| Alvotech | 1.06 Billion USD | 109.087% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 1453.534% |
| Currenc Group, Inc. | -16.57 Million USD | -483.535% |
| Kamada Ltd. | -46.43 Million USD | -108.285% |
| Indivior PLC | -33.95 Million USD | -184.843% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 37214.217% |
| Flora Growth Corp. | -713 Thousand USD | -13463.815% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -1077.455% |
| Evolus, Inc. | 63.7 Million USD | 251.802% |
| HUTCHMED (China) Limited | -197.45 Million USD | 51.022% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 120.185% |
| Akanda Corp. | 3.9 Million USD | 2576.622% |